<DOC>
	<DOCNO>NCT02218320</DOCNO>
	<brief_summary>This Phase IV , open label , observational study compare gastrointestinal tissue concentration , inflammatory response , viral replication two integrase-inhibitors , raltegravir dolutegravir , HIV-infected volunteer virologically suppress blood plasma . The study comprise 20 HIV-infected volunteer enrol equally two group . Group A consist 10 subject receive antiretroviral regimen tenofovir , emtricitabine , raltegravir , Group B consist 10 subject receive antiretroviral regimen tenofovir , emtricitabine , dolutegravir . Participants provide small piece tissue , biopsy , take three distinct location large intestine colonoscopy procedure . These biopsy use measure amount raltegravir dolutegravir , HIV virus , inflammatory marker present gastrointestinal tract .</brief_summary>
	<brief_title>Comparison Virologic Immunologic Responses Raltegravir Dolutegravir Gastrointestinal Tract HIV-Positive Adults</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy HIVpositive adult age 1865 , inclusive date screening , documentation least one positive HIV test . Healthy define clinically relevant abnormality would interfere interpretation result , pose unnecessary risk onto volunteer due study procedure . Receiving antiretroviral regimen contain tenofovir+emtricitabine raltegravir ( Group A ) dolutegravir ( Group B ) &gt; 3 month , blood plasma HIV RNA &lt; 50copies/mL least 4 week , 2 log decrease baseline blood plasma HIV RNA . Evidence personally sign date informed consent document indicate subject inform pertinent aspects trial . Documentation least 80 % adherence antiretroviral regimen , clinician selfreport , miss dos 3 day prior inpatient visit . Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Women childbearing potential must utilize least one acceptable form birth control . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease would pose unnecessary risk interfere study result . Subjects excluded condition would increase risk sedation , endoscopy , biopsy . Subjects history gastrectomy , colostomy , ileostomy , clinically significant procedure alter gastrointestinal tract , condition possibly affect drug absorption . Subjects inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) . Female subject currently pregnant breastfeed , plan become pregnant study period . Subjects unwilling refrain insertion medical/recreation device product rectum , receptive anal intercourse , 72 hour inpatient study visit 7 day last biopsy unless instructed otherwise investigator . A positive urine drug screen . Untreated rectal sexually transmit infection screen . Treatment investigational drug within 2 month precede study enrollment . Participated gastrointestinal biopsy study 3 month precede study enrollment . Participants history clot bleed disorder . Participants history abnormal reaction , complication , conscious sedation anesthesia Subjects unwilling unable comply follow dietary restriction regard study procedure , include clear liquid diet bowel preparation period NPO ( nil per o ) prior colonoscopy . While confine , total daily nutritional composition 50 % carbohydrate , 15 % protein , 35 % fat . The daily caloric intake exceed 3200kcal . Abnormalities colorectal mucosa , significant colorectal symptom ( ) , opinion clinician represent contraindication biopsy ( include limit presence unresolved injury , infectious inflammatory condition local mucosa , presence symptomatic external hemorrhoid ) . Any reason condition judgment investigator would make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Gut-associated lymphoid tissue</keyword>
	<keyword>raltegravir</keyword>
	<keyword>Isentress</keyword>
	<keyword>dolutegravir</keyword>
	<keyword>Tivicay</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>